The primary end point of the Phase 3 LELANTOS-2 Trial for the Duchenne Agent Pamrevlumab is not met.

Published Date: 03 Sep 2023

Pamrevlumab, a potential first-in-class connective tissue growth factor inhibitor antibody, is generally safe and well tolerated but failed to reach its primary endpoint in a phase 3 trial for ambulator Duchenne muscular dystrophy.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

When Should Immunocompromised Individuals Receive a COVID Booster?

2.

Home Screening Appeals to Women Facing Healthcare Barriers

3.

Quality of Life Similar With Proton Beam Therapy vs IMRT for Prostate Cancer

4.

Prolonged Screen Time Linked to Sleep Issues in Preschoolers

5.

Precision Medicine in mHSPC: Integrating Novel Biomarkers, Imaging, and Emerging Targeted Agents


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot